Posts Tagged ‘VIH’

Friday February 17th, 2017

A therapeutic HIV vaccine clinical trial induces viral control in 5 people without taking antiretroviral therapy

A therapeutic HIV vaccine clinical trial showed, for the first time, that in some cases the immune system of HIV infected people can be reeducated to control the virus for long periods without taking antiretroviral treatment. In particular, 5 out of 13 participants who stopped treatment (38.5%) have been controlling the virus for 5, 13, 17, 20 and 27 weeks, respectively. The study, still ongoing, is conducted in Barcelona and tests a vaccine developed by researchers at Oxford University in combination with a drug, romidepsin, able to awaken latent viruses in the body. The study is conducted by IrsiCaixa and the Fight AIDS Foundation and performed at the ospital Clínic de Barcelona-IDIBAPS, the Germans Trias i Pujol University Hospital (Barcelona) and the community center BCN Checkpoint. Read the rest of this entry »

Comments Closed
Thursday November 10th, 2016

Scientists from the European AIDS Vaccine Initiative (EAVI2020) meet in Barcelona to analyze the results of the first year of the consortium

Scientists from 22 institutions in Europe, Australia, Canada and the United States meet in Barcelona on November 10-11 to discuss the trajectory and progress of the European AIDS Vaccine Initiative (EAVI2020). This initiative, funded by the European Commission with 23 million euro, started a year ago to accelerate the development of an effective vaccine against HIV. The three Spanish centers participating in the consortium are the IrsiCaixa AIDS Research Institute, which organizes the meeting in Barcelona, the IDIBAPS and the Institute of Health Carlos III. The participation of IrsiCaixa and IDIBAPS is part of HIVACAT, the Catalan research project for an AIDS vaccine.

Read the rest of this entry »

Comments Closed

Categories

Posted in:

Tuesday February 02nd, 2016

IDIBAPS takes part in a 30 million euros project to develop new HIV vaccines

IDIBAPS takes part in the European HIV Vaccine Alliance (EHVA) to develop and evaluate new preventive and therapeutic vaccines. The European Commission grants with over 22 million euros in addition to the 6 million euros from Swiss Government. This effort is part of the European Commission Framework Programme for Research and Innovation (Horizon2020) and gathers together HIV leading scientists from 39 public institutions along with European, North American and African companies. Dr. Josep M. Gatell, head of the Infectious Diseases and AIDS IDIBAPS team, is the coordinator from this centre, and Drs. Felipe García, Montserrat Plana and Eloisa Yuste, researchers from the same group, also would join the project. The Spanish National Centre for Biotechnology of the CSIC (CNB-CSIC) also participates.

Read the rest of this entry »

Comments Closed

Categories

Posted in:

Monday November 02nd, 2015

IDIBAPS and IrsiCaixa participate in a 23 million euro project to develop HIV vaccine

IDIBAPS and the IrsiCaixa AIDS Research Institute participate in the European AIDS Vaccine Initiative (EAVI2020), a project to to accelerate the search for an effective HIV vaccine. This initiative, that is part of the European Comission framework programme for research and innovation (Horizon2020), brings together leading HIV researchers from public organisations and biotech companies from across Europe, Australia, Canada and the USA. IrsiCaixa and IDIBAPS are members of this consortium in which participate 22 institutions. Dr. Joan Joseph, researcher at the Infectious Diseases and AIDS IDIBAPS team led by Dr. Josep M. Gatell, will coordinate the project conducted at IDIBAPS over the next 5 years. At IrsiCaixa, an institute led by Dr. Bonaventura Clotet, this project will be coordinated by Dr. Christian Brander, head of the Host Cellullar and Genetic Immunity group and member of the consortium’s steering comitee. The other spanish participant in the consortium is the Instituto de Salud Carlos III.

Read the rest of this entry »

Comments Closed
Friday June 12th, 2015

Hospital Clinic will coordinate the validation of an european ‘app’ to better monitor HIV patients

Researchers from the Hospital Clinic of Barcelona participate in the development and subsequent validation of an application for mobile devices that will facilitate monitoring of HIV patients and the doctor-patient communication. In the European project EmERGE, Hospital Clinic will validate the use of a mHealth platform in a study with 4,000 patients across Europe, 1.000 of whom will be participants of this center. The project, launched last May 6th and coordinated by the University of Sussex (UK), is part of Horizon 2020, the European Comission framework programme for research and innovation, it is endowed with a budget of 6 million euros and includes the participation of several European institutions.

Read the rest of this entry »

Comments Closed
Tuesday January 20th, 2015

A novel antiviral combination has proven to be effective against hepatitis C virus in patients with HIV

Around 150 million people worldwide are infected with the hepatitis C virus (HCV) and about 5 million are also co-infected by the HIV virus. A study published in the prestigious journal The Lancet demonstrated efficacy in the treatment of HCV in HIV-infected patients with the single or combined use of two drugs administered for 12 weeks. Dr. Josep Mallolas, consultant of the Infectious Diseases Department at Hospital Clínic and researcher at the Infectious Diseases and AIDS group at IDIBAPS, has participated in the study. Hospital Clinic has been the only Spanish center that has participated in this clinical trial.

Read the rest of this entry »

Comments Closed
Page 1 of 212